請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6235
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李正? | |
dc.contributor.author | Tsung-Hsun Ho | en |
dc.contributor.author | 何宗訓 | zh_TW |
dc.date.accessioned | 2021-05-16T16:23:47Z | - |
dc.date.available | 2013-09-24 | |
dc.date.available | 2021-05-16T16:23:47Z | - |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-04 | |
dc.identifier.citation | 1. Neville BW. Oral and maxillofacial pathology: Saunders/Elsevier; 2009.
2. Shah JP, Snehal G. Patel MD, Singh B. Head and Neck Surgery and Oncology: Elsevier/Mosby; 2012. 3. Ko Y, Huang Y, Lee C. Betal quid chewing, smoking and alcohol consumption realted to oral cancer in Taiwan. J Oral Pathol Med 1995;24:450-3. 4. Chen YK, Huang HC, Lin LM, Lin CC. Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral oncology 1999;35:173-9. 5. Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Annals of surgical oncology 2008;15:915-22. 6. Shah J. Head and Neck Surgery. 2nd ed; 2002. 7. Neville, Damm, Allen, Bouquot. Oral and Maxillofacial Pathology. 2 ed; 2002. 8. Chen YJ, Chang JT, Liao CT, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer science 2008;99:1507-14. 9. Watts JM. The importance of the Plummer-Vinson syndrome in the aetiology of carcinoma of the upper gastrointestinal tract. Postgraduate medical journal 1961;37:523-33. 10. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral oncology 1997;33:231-6. 11. Krogh P, Hald B, Holmstrup P. Possible mycological etiology of oral mucosal cancer: catalytic potential of infecting Candida albicans and other yeasts in production of N-nitrosobenzylmethylamine. Carcinogenesis 1987;8:1543-8. 12. Dickenson AJ, Currie WJ, Avery BS. Screening for syphilis in patients with carcinoma of the tongue. The British journal of oral & maxillofacial surgery 1995;33:319-20. 13. Niv A, Sion-Vardi N, Gatot A, Nash M, Fliss DM. Identification and typing of human papillomavirus (HPV) in squamous cell carcinoma of the oral cavity and oropharynx. The Journal of laryngology and otology 2000;114:41-6. 14. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature reviews Cancer 2011;11:9-22. 15. Partridge M, Kiguwa S, Emilion G, Pateromichelakis S, A'Hern R, Langdon JD. New insights into p53 protein stabilisation in oral squamous cell carcinoma. Oral oncology 1999;35:45-55. 16. Sheu JJ, Hua CH, Wan L, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer research 2009;69:2568-76. 17. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-8. 18. Zahorowska B, Crowe PJ, Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. Journal of cancer research and clinical oncology 2009;135:1137-48. 19. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67. 20. Munder M, Mallo M, Eichmann K, Modolell M. Direct stimulation of macrophages by IL-12 and IL-18 - a bridge built on solid ground. Immunology letters 2001;75:159-60. 21. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nature immunology 2000;1:475-82. 22. Golab J, Zagozdzon, Stoklosal T, Kaminski R, Kozar K, Jakobisiak M. Direct stimulation of macrophages by IL-12 and IL-18--a bridge too far? Immunology letters 2000;72:153-7. 23. Flaishon L, Hershkoviz R, Lantner F, et al. Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. The Journal of experimental medicine 2000;192:1381-8. 24. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. Journal of immunology 1998;161:3400-7. 25. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. The Journal of experimental medicine 1998;187:2103-8. 26. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annual review of immunology 1997;15:563-91. 27. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. The oncologist 2001;6:34-55. 28. Bazer FW, Spencer TE, Ott TL. Interferon tau: a novel pregnancy recognition signal. Am J Reprod Immunol 1997;37:412-20. 29. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends in immunology 2001;22:556-60. 30. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. The Journal of allergy and clinical immunology 1999;103:11-24. 31. Sen GC. Viruses and interferons. Annual review of microbiology 2001;55:255-81. 32. Thoreau E, Petridou B, Kelly PA, Djiane J, Mornon JP. Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS letters 1991;282:26-31. 33. Farrar MA, Fernandez-Luna J, Schreiber RD. Identification of two regions within the cytoplasmic domain of the human interferon-gamma receptor required for function. The Journal of biological chemistry 1991;266:19626-35. 34. Kotenko SV, Izotova LS, Pollack BP, et al. Interaction between the Components of the Interferon Receptor Complex. Journal of Biological Chemistry 1995;270:20915-21. 35. Ealick SE, Cook WJ, Vijay-Kumar S, et al. Three-dimensional structure of recombinant human interferon-gamma. Science 1991;252:698-702. 36. Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors--an intimate relationship. Biochemical pharmacology 2006;72:1538-46. 37. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature reviews Immunology 2005;5:375-86. 38. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. Journal of leukocyte biology 2004;75:163-89. 39. Zhong M, Henriksen MA, Takeuchi K, et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proceedings of the National Academy of Sciences of the United States of America 2005;102:3966-71. 40. Kramer OH, Knauer SK, Greiner G, et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes & development 2009;23:223-35. 41. Marine JC, Topham DJ, McKay C, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999;98:609-16. 42. Alexander WS, Starr R, Fenner JE, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608. 43. Kramer OH, Baus D, Knauer SK, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes & development 2006;20:473-85. 44. Choudhury GG. A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. The Journal of biological chemistry 2004;279:27399-409. 45. Seliger B, Ruiz-Cabello F, Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Advances in cancer research 2008;101:249-76. 46. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. Journal of clinical immunology 2003;23:147-61. 47. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunological reviews 2008;226:41-56. 48. Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Annals of the New York Academy of Sciences 2009;1182:69-79. 49. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. Journal of immunology 1987;139:2977-83. 50. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56. 51. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 1998;95:7556-61. 52. Weber JS, Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer research 1988;48:5818-24. 53. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E, Gillitzer R. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. The Journal of pathology 1999;189:552-8. 54. Mukai S, Kjaergaard J, Shu S, Plautz GE. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer research 1999;59:5245-9. 55. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996;272:719-22. 56. Hobeika AC, Etienne W, Torres BA, Johnson HM, Subramaniam PS. IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19:1351-61. 57. Platanias LC, Uddin S, Bruno E, et al. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Experimental hematology 1999;27:1315-21. 58. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. Journal of immunology 2001;166:2276-82. 59. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34. 60. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nature medicine 1998;4:408-14. 61. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis : an international journal on programmed cell death 2003;8:237-49. 62. Kloke O, Wandl U, Opalka B, et al. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. European journal of haematology 1992;48:93-8. 63. Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 1987;70:943-7. 64. Fisher PB, Miranda AF, Babiss LE. Measurement of the effect of interferons on cellular differentiation in murine and human melanoma cells. Methods in enzymology 1986;119:611-8. 65. Kortylewski M, Komyod W, Kauffmann ME, Bosserhoff A, Heinrich PC, Behrmann I. Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. The Journal of investigative dermatology 2004;122:414-22. 66. Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. Stat1-independent regulation of gene expression in response to IFN-gamma. Proceedings of the National Academy of Sciences of the United States of America 2001;98:6674-9. 67. Taniguchi K, Petersson M, Hoglund P, Kiessling R, Klein G, Karre K. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proceedings of the National Academy of Sciences of the United States of America 1987;84:3405-9. 68. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. International journal of cancer Journal international du cancer 1988;41:562-7. 69. Garbe C, Krasagakis K, Zouboulis CC, et al. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. The Journal of investigative dermatology 1990;95:231S-7S. 70. Bernabei P, Coccia EM, Rigamonti L, et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. Journal of leukocyte biology 2001;70:950-60. 71. Lollini PL, Bosco MC, Cavallo F, et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. International journal of cancer Journal international du cancer 1993;55:320-9. 72. Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2:29-36. 73. Meyskens FL, Jr., Kopecky K, Samson M, et al. Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. Journal of the National Cancer Institute 1990;82:1071. 74. Meyskens FL, Jr., Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. Journal of the National Cancer Institute 1995;87:1710-3. 75. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17:6118-24. 76. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70. 77. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nature reviews Immunology 2008;8:74-80. 78. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunological reviews 2008;222:206-21. 79. Brody JR, Costantino CL, Berger AC, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009;8:1930-4. 80. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008;27:3889-900. 81. Peters JC. Tryptophan nutrition and metabolism: an overview. Advances in experimental medicine and biology 1991;294:345-58. 82. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA. Tryptophan metabolism in the central nervous system: medical implications. Expert reviews in molecular medicine 2006;8:1-27. 83. Higuchi K, Hayaishi O. Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys 1967;120:397-403. 84. Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochemical and biophysical research communications 2005;338:12-9. 85. Shimizu T, Nomiyama S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. The Journal of biological chemistry 1978;253:4700-6. 86. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1991;5:2516-22. 87. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3. 88. Watanabe Y, Yoshida R, Sono M, Hayaishi O. Immunohistochemical localization of indoleamine 2,3-dioxygenase in the argyrophilic cells of rabbit duodenum and thyroid gland. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1981;29:623-32. 89. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proceedings of the National Academy of Sciences of the United States of America 2006;103:2611-6. 90. Sono M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. Biochemistry 1989;28:5400-7. 91. Kadoya A, Tone S, Maeda H, Minatogawa Y, Kido R. Gene structure of human indoleamine 2,3-dioxygenase. Biochemical and biophysical research communications 1992;189:530-6. 92. Najfeld V, Menninger J, Muhleman D, Comings DE, Gupta SL. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12-->p11 by fluorescent in situ hybridization. Cytogenetics and cell genetics 1993;64:231-2. 93. Koukouritaki SB, Poch MT, Henderson MC, et al. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. The Journal of pharmacology and experimental therapeutics 2007;320:266-73. 94. Boyland E, Williams DC. The estimation of tryptophan metabolites in the urine of patients with cancer of the bladder. The Biochemical journal 1955;60:v. 95. Rose DP. Tryptophan metabolism in carcinoma of the breast. Lancet 1967;1:239-41. 96. Wolf H, Madsen PO, Price JM. Studies on the metabolism of tryptophan in patients with benign prostatic hypertrophy or cancer of the prostate. The Journal of urology 1968;100:537-43. 97. Ambanelli U, Rubino A. Some aspects of tryptophan--nicotinic acid chain in Hodgkin's disease. Relative roles of tryptophan loading and vitamin supplementation on urinary excretion of metabolites. Haematologica Latina 1962;5:49-73. 98. Ivanova VD. Disorders of Tryptophan Metabolism in Leukaemia. Acta - Unio Internationalis Contra Cancrum 1964;20:1085-6. 99. Hayaishi O RY, Takikawa O, Yasui H. Indoleamine-dioxygenase-a possible biological function. Progress in Tryptophan and Seratonin Research. Berlin: Walter De Gruyter and Co 1984:33-42. 100. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Laboratory investigation; a journal of technical methods and pathology 2003;83:1457-66. 101. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. The Journal of clinical investigation 2004;114:280-90. 102. Wolf AM, Wolf D, Rumpold H, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004;113:47-55. 103. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11:6030-9. 104. Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005;7:390-6. 105. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12:1144-51. 106. Nakamura T, Shima T, Saeki A, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98:874-81. 107. Laimer K, Troester B, Kloss F, et al. Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 2011;47:352-7. 108. Chen W. IDO: more than an enzyme. Nature immunology 2011;12:809-11. 109. Zaidi MR, De Fabo EC, Noonan FP, Merlino G. Shedding light on melanocyte pathobiology in vivo. Cancer research 2012;72:1591-5. 110. Johnson HM, Noon-Song EN, Kemppainen K, Ahmed CM. Steroid-like signalling by interferons: making sense of specific gene activation by cytokines. The Biochemical journal 2012;443:329-38. 111. Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNgamma signaling-does it mean JAK-STAT? Cytokine & growth factor reviews 2008;19:383-94. 112. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer research 2007;67:7082-7. 113. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008;111:2152-4. 114. Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer immunology, immunotherapy : CII 2009;58:153-7. 115. Jia L, Schweikart K, Tomaszewski J, et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2008;46:203-11. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6235 | - |
dc.description.abstract | 背景
Indoleamine 2,3-Dioxygenase(IDO)為控管人體中Tryptophan(Trp)代謝重要酵素,藉由促進其代謝,產生抑制T cell的活性及加速T cell凋亡的效果,以達免疫抑制之功效。在正常的生理狀態下,IDO常表現於母體的胎盤內,做為抑制免疫的角色以避免同種異體的胎兒遭受母體免疫系統的攻擊。在惡性腫瘤中,受到了Interferon-gamma(IFN﹣γ)刺激,IDO的大量表現扮演了幫助腫瘤細胞脫逃出免疫系統的監控與攻擊的角色(immune escape),在人體癌症中如大腸癌、膀胱癌及乳癌等,其表現量都有提高的情形,且與腫瘤的分期(stage)甚至癒後(prognosis)都有顯著的相關性。本研究欲探討IDO與IFN﹣γ於口腔鱗狀細胞癌(OSCC)之病理組織中的表現量,並且分析其臨床各參數和存活時間之關係。 材料與方法 本研究目的在於探討IDO與IFN﹣γ於62例OSCC中的表現,藉由免疫組織化學染色方法,並以陽性染色指標Labeling index(LI)記錄其染色程度。利用Student T test及ANOVA分析其平均值差異;點二系列相關(point-biserial correlation)、皮爾森相關(Pearson correlation)、斯皮爾曼相關(Spearman correlation)分析其相關性;Linear regression分析IDO和IFN﹣γ之因果關係;Cox proportional hazard regression model及Kaplan-Meier 存活率方法來分析口腔鱗狀細胞癌患者臨床病理參數及存活率與IDO及IFN﹣γ的表現之相關性,並分析是否有影響存活時間的獨立預後因子。 結果 在口腔鱗狀細胞癌的組織中,IDO的平均陽性標記指數為27.26%,IFN﹣γ的平均陽性標記指數為55.81%;其中IDO高表現(LI≥40)的樣本佔所有樣本之27.12﹪,IFN﹣γ(LI≥40)高表現的樣本佔所有樣本之79.66%。二者陽性標記指數有顯著相關性(p=0.001),相關係數為0.41,R square為0.17。 IDO的陽性標記指數與腫瘤的大小(T status)及腫瘤分期(stage)有顯著相關(p=0.22)(p=0.05)。在邊緣侵犯的腫瘤中,IFN﹣γ的表現量與未侵犯的組別相比有顯著的增加,且有表現量與侵犯與否有相關性;而與周邊淋巴血管侵犯與否有相關性。 其餘各項臨床參數中,都與IDO和IFN﹣γ之表現沒有顯著相關性。在單變量之Cox proportional hazard regression model中,IDO之陽性標記指數,淋巴結轉移分期(N status)及腫瘤分化(differentiation)為顯著存活因子。在多變量之Cox proportional hazard regression model中,僅淋巴結轉移分期(N status)為其顯著存活因子。 在Kaplan-Meier plots中,IDO陽性染色指標顯著地縮短病人之總存活時間(overall survival),Log-Rank Test之p值為 0.037。IFN﹣γ陽性染色指標則有縮短病人總存活時間之趨勢,但未達統計意義。 結論 於本研究中,IN﹣γ的陽性染色指標與IDO的陽性染色指標有顯著關聯性。IDO的陽性染色指標與腫瘤大小及口腔癌分期有顯著關聯性,且與口腔細胞癌患者的存活時間有關。在口腔癌患者中,IDO的表現量較高者其存活時間較短。 | zh_TW |
dc.description.abstract | Background
Indoleamine 2,3-Dioxygenase(IDO)regulates the catabolism of Tryptophan(Trp) and suppresses T cells proliferation and enhances T cells apoptosis by consuming Trp. In normal physical status, IDO expresses in planceta preventing allogenic fetal rejection by catabolism of Trp. Expression of IDO in malignant tumor, elevated by the effect of IFN-γ, plays an important role in the mechanism of the immune escape which is the cell extrinsic traits of cancers. Many researches reveal increasing IDO level in malignant tumor, including colon cancer, bladder cancer and breast cancer, etc., related to the advanced stage and poor prognosis. The emphasis of this study is on the expressions of IDO and IFN-γ in pathological specimens from oral squamous cell carcinoma(OSCC)and the correlation between these expressions, clinical and pathologic parameters, and the survival time. Materials and Methods The goal in this study is examining the expression of IDO and IFN-γ in 62 specimens diagnosed as OSCC by immunohistochemistry(IHC) staining and recording the grade of positive staining as labeling index(LI). The correlations between the expression of IDO and IFN-γ, clinical and pathological parameter, the disease-free survival and overall survival were analyzed via student T test, ANOVA, linear regression, correlation analysis, including point-biserial correlation, Pearson correlation, Spearman correlation, Survival analysis, including Cox proportional hazard regression model and Kaplan-Meier plots. Results The average labeling index of IDO in OSCC specimens is 27.26%, and the average labeling index of IFN-Υ is 55.81%. The rate of specimens with high-IDO expression (LI≥40) in all OSCC specimens is 27.12% and the rate of the specimens with high-IFN-γ expression is 79.66%. The expressions of IDO and IFN-γ have significant correlation between each over (p=0.001), R=0.41 The labeling index of IDO has significant correlation between T status and tumor stage (p=0.22) (p=0.05). In the group with marginal involvement, the labeling index of IFN-γ is elevated significantly and there is a significant correlation between marginal involvement and LI of IFN-γ. The correlation between lymphovascular invasion and LI of IFN-γ is significant too. There is no correlation between the other clinical parameters and the expression of IDO and IFN-γ. In univariate Cox proportional hazard regression model, LI of IDO, N status and tumor differentiation are statistically significant. In multivariate Cox proportional hazard regression model, only N status is significant. Kaplan-Meier survival analysis showed that patients had shorter overall survival time with high LI of IDO. The Log-Rank Test p value is 0.037. High LI of IFN-γ indicates the tendency of decreasing overall survival time in OSCC patients, but is not statistically significant. Conclusions The labeling index of IDO has significant correlation with the labeling index of IFN-γ, T status of tumor, and tumor stage. In OSCC patients, high expression of IDO indicates shorter overall survival. IDO and IFN-γ may have influence on each other and indicate advanced tumor stage and poor prognosis. | en |
dc.description.provenance | Made available in DSpace on 2021-05-16T16:23:47Z (GMT). No. of bitstreams: 1 ntu-102-R00422011-1.pdf: 3616145 bytes, checksum: c4ac524bf4fb1d10bd2824cd56ebbcd9 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 第一章序論及文獻回顧 1
1.1 口腔鱗狀細胞癌(ORAL SQUAMOUS CELL CARCINOMA, OSCC)概論 1 1.1.1口腔鱗狀細胞癌簡介 1 1.1.3口腔鱗狀細胞癌之危險因子及基因變異 3 1.1.4口腔鱗狀細胞癌之臨床分期 5 1.1.5現行對口腔鱗狀細胞之治療及預後 6 1.2 IFN-Γ概論 7 1.2.1 Interferon 7 1.2.2 IFN-γ receptor 8 1.2.3 IFN-γ signaling pathway 8 1.3 IFN-Γ與癌症之關係 9 1.3.1 IFN-γ之正向作用 9 1.3.2 IFN-γ之負向作用 10 1.4 IDO概論 11 1.4.1 Tryptophan metabolism pathway及IDO結構 11 1.5 IDO與癌症之關係 12 第二章材料與方法 15 2.1 實驗樣本 15 2.2 標本之固定與包埋 15 2.3 免疫組織化學染色(IMMUNOHISTOCHEMISTRY STAIN) 15 2.3.1反應原理 15 2.3.2初級抗體(primary antibody)的選擇 16 2.3.3 抗原抗體結合之偵測系統 16 2.3.4實驗步驟 17 2.4 免疫組織化學染色後之觀察與記錄 19 2.4.1觀察 19 2.4.2染色程度之定量 19 2.4.3臨床變數之紀錄 20 2.4.4統計分析 20 第三章結果 22 3.1 IDO和IFN-Γ於口腔鱗狀細胞癌(OSCC)之表現 22 3.2 免疫組織化學染色結果與患者臨床及組織病理各項參數之關係 23 3.3 IDO及IFN-Γ免疫組織化學染色與臨床參數之單變數(UNIVARIATE)、多變數(MULTIVARIATE)分析 29 3.4 IDO和IFN-Γ表現與存活時間分析(SURVIVAL ANALYSIS) 30 第四章討論 31 4.1 IDO和IFN-Γ於口腔鱗狀細胞癌組織切片之免疫組織化學染色情形 31 4.2 由臨床參數的危險因子的統計意義推測IDO和IFN-Γ在口腔鱗狀細胞癌中可能的作用機轉 31 4.3 IDO做為口腔鱗狀細胞癌治療可能的藥物投與標的 32 第五章結論 34 參考文獻 35 附表與附圖 44 | |
dc.language.iso | zh-TW | |
dc.title | "Indoleamine 2,3-Dioxygenase及Interferon-gamma於口腔鱗狀細胞癌中之表現" | zh_TW |
dc.title | Expression of Indoleamine 2,3-Dioxygenase and Interferon-gamma in oral squamous cell carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 賈景山 | |
dc.contributor.oralexamcommittee | 王萬波,江俊斌,郭生興 | |
dc.subject.keyword | IDO,IFN﹣γ,口腔鱗狀細胞癌, | zh_TW |
dc.subject.keyword | IDO,IFN-γ,oral squamous cell carcinoma, | en |
dc.relation.page | 57 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2013-07-05 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf | 3.53 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。